Retatrutide is an unlicensed triple incretin receptor agonist (GLP-1, GIP, glucagon) still in clinical trials
FDAs career scientists have made clear they dont think theres enough data to support making peptides more widely available, specifically from compounding pharmacies, which mix customized medicines that arent available from traditional drugmakers
Instead they rose out of the quest to unravel the complex physiology of the gut and its diseases, particularly diabetes
The liver is responsible for filtering toxins, heavy metals, alcohol, and medications from the bloodstream, and glutathione acts as a shield binding to these harmful substances and facilitating their elimination
This review seeks to resolve the apparent contradictions in the literature and propose future research directions centered on appropriate patient populations and therapeutic windows